GlassScriptPhysician profile
Gary P Engstrom
NPI 1336149731
$9,261.11
in general payments reported to CMS, 2019-2025
77 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $1,129 · 2021: $656 · 2022: $1,707 · 2023: $1,974 · 2024: $1,487 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,545 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,545.39 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $650.92 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $622.06 | 2019-2024 | Imfinzi, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $604.56 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $518.35 | 2019-2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $402.53 | 2019-2024 | Carvykti, Tecvayli, Rybrevant |
| Amgen INC. | $375.98 | 2019-2023 | Nplate, Vectibix, Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $315.05 | 2019-2024 | Fruzaqla, Ninlaro, Vonvendi |
| Celgene Corporation | $284.07 | 2019-2024 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $261.97 | 2019-2024 | Opdivo, Opdualag |
| Genzyme Corporation | $258.07 | 2019-2024 | |
| Genentech USA, INC. | $246.32 | 2019-2024 | Tecentriq, Columvi, Lunsumio |
| Incyte Corporation | $230.85 | 2019-2024 | Jakafi, Monjuvi |
| Coherus Oncology, INC. | $219.04 | 2020-2025 | Loqtorzi |
| Bayer Healthcare Pharmaceuticals INC. | $209.51 | 2019-2023 | |
| Seagen INC. | $199.39 | 2020-2023 | Padcev, Tukysa |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Engstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.